Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors
Based On Veteran Researcher’s Innovation
Executive Summary
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
You may also be interested in...
Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.